Pfizer Says COVID Vaccine Is Secure, Efficient for Youngsters 5-11

Sept. 20, 2021 — With report numbers of COVID-19 instances being reported in children, Pfizer and its companion BioNTech have introduced that their mRNA vaccine for COVID-19 is secure and seems to generate a protecting immune response in youngsters as younger as 5.

The businesses have been testing a decrease dose of the vaccine — simply 10 milligrams — in youngsters between the ages of 5 and 11. That’s one-third the dose given to adults.

In a medical trial that included greater than 2,200 youngsters, Pfizer says two doses of the vaccines given 3 weeks aside generated a excessive stage of neutralizing antibodies, corresponding to the extent seen in older youngsters who get the next dose of the vaccine.

On the recommendation of its vaccine advisory committee, the FDA requested vaccine makers to incorporate extra youngsters in these research earlier this 12 months.

Slightly than testing whether or not the vaccines are stopping COVID-19 sickness in youngsters, as they did in adults, the pharmaceutical firms that make the COVID-19 vaccines are wanting on the antibody ranges generated by the vaccines as a substitute. The FDA has authorized the method in hopes of rushing vaccines to youngsters, who are actually again at school full time in most elements of the U.S.

With that in thoughts, Evan Anderson, MD, a physician with Kids’s Healthcare of Atlanta who’s an investigator for the trial — and is due to this fact stored at midnight about its outcomes — stated it’s essential to remember the fact that the corporate didn’t share any efficacy knowledge immediately. 

“We don’t know whether or not there have been instances of COVID-19 amongst youngsters that have been enrolled within the examine and the way these in contrast in those that obtained placebo versus those who obtained vaccine,” he stated.

The corporate says unwanted effects seen within the trial are corresponding to these seen in older youngsters.  The corporate stated there have been no instances of coronary heart irritation known as myocarditis noticed. Pfizer says they plan to ship their knowledge to the FDA as quickly as doable.

The corporate says unwanted effects seen within the trial are corresponding to these seen in older youngsters. Pfizer says they plan to ship their knowledge to the FDA as quickly as doable.

“We’re happy to have the ability to submit knowledge to regulatory authorities for this group of school-aged youngsters earlier than the beginning of the winter season,” Ugur Sahin, MD, CEO and co-founder of BioNTech, stated in a information launch. “The protection profile and immunogenicity knowledge in youngsters aged 5 to 11 years vaccinated at a decrease dose are in keeping with these we now have noticed with our vaccine in different older populations at the next dose.”

When requested how quickly the FDA may act on Pfizer’s utility, Anderson stated others had speculated about timelines of 4 to six weeks, however he additionally famous that the FDA may nonetheless train its authority to ask the corporate for extra data, which may sluggish the method down.

“As a father or mother myself, I’d like to see that timeline occurring rapidly.  Nonetheless, I do need the FDA to completely evaluation the info and ask the mandatory questions,” he stated. “It’s somewhat speculative to get too definitive with timelines.”

WebMD Well being Information


Information launch, Pfizer, Sept. 20, 2021.

Evan Anderson, MD, Kids’s Healthcare of Atlanta.

© 2021 WebMD, LLC. All rights reserved.

We will be happy to hear your thoughts

Leave a reply

Enable registration in settings - general
Compare items
  • Total (0)
Shopping cart